Symbols

VRCA

Verrica·NASDAQ

--(--)

VRCA fundamentals

VRCA Q4 2025 Earnings

Verrica (VRCA) released its earnings on Mar 11, 2026: revenue was 5.09M (YoY +1380.23%), beat estimates; EPS was -0.57 (YoY +76.25%), beat estimates.

Revenue / YoY

5.09M

+1380.23%

EPS / YoY

-0.57

+76.25%

Report date

Mar 11, 2026

VRCA Earnings Call Summary for Q4,2025

Revenue Surge: YCANTH revenue up 130% YoY in 2025, with Q4 2025 dispensed units up 58% YoY and February 2026 at record highs.
Pipeline Momentum: Phase III for YCANTH in common warts dosed first patient in Q4 2025; VP-315 Phase III design aligned with FDA, targeting 2026启动.
Financial Resilience: $50M equity raise extended cash runway to 2027, with $30.1M cash as of Q4 2025 and debt fully retired.
Global Expansion: YCANTH launched in Japan (February 2026) and progressing toward EU approval, with CHMP positive feedback in 2025.
Cost Efficiency: SG&A down 40% YoY, R&D expenses down 21% YoY, supporting disciplined growth strategy.

Earnings

EPS

Revenue

Revenue & Expenses

VRCA has released its 2025 Q4 earnings report, with revenue of 5.09M, reflecting a YoY change of 1380.23%, and net profit of -8.07M, showing a YoY change of 50.17%. The Sankey diagram below clearly presents VRCA's revenue sources and cost distribution.

Key Indicators

Verrica (VRCA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Verrica (VRCA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Verrica (VRCA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Verrica (VRCA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown